Phase II Trial Of Campath-1H In Patients With Relapsed/Refractory Advanced Mycosis Fungoides Or Sezary Syndrome
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2016
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Mycosis fungoides; Sezary syndrome
- Focus Adverse reactions; Therapeutic Use
- 23 Feb 2016 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018 as reported by ClinicalTrials.gov.
- 23 Feb 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017 as reported by ClinicalTrials.gov.
- 19 Feb 2015 Planned End Date changed from 1 Aug 2015 to 1 Aug 2017, according to the ClinicalTrials.gov record.